The CBD portion of the trial is double blind and is a good design. The open label "add-on THC" arm will be subject to bias and has no comparator, so I do not see the benefit of studying it this way. Also, the merit of combination CBD:THC in responders would be useful to know.
The dose ratio of CBD to THC is potentially very variable. The Sativex product is a 1:1 ratio of the two drugs, whereas in this study CBD:TCH could potentially be 1.3:1 to 12:1, and will make interpretation of the THC component of the study even less reliable.
No study date is mentioned in the protocol, so I am not sure whether it is still not too late to make changes in the study design based on my comments. 
GENERAL COMMENTS
This paper addresses a significantly important topic, the research methods and study design needs some clarification in the paper. I have made numerous suggested changes and/or additions throughout the manuscript.
-The reviewer also provided a marked copy with additional comments. Please contact the publisher for full details.
VERSION 1 -AUTHOR RESPONSE
Comments to the Authors A. Reviewer 1: Dr. M. G. Serpell "This research is welcome because Cannabinoids are an important area to research with regards to pain relief and side effects. The outcome measures include parameters recommended by the IMMPACT paper.
[1]" a. Thank you very much. This fact is important and we chose to add the IMMPACT paper as reference 44.
"The protocol does not justify why patients with AS & RA of "low disease activity" versus other levels of activity are selected. Could the authors please explain this."
b. High disease activity in Rheumatoid arthritis and spondyloarthritis is defined as inflammatory activity, characterized by clinical, radiographic and/or biochemical findings of inflammation. Conventional and biologic disease modifying anti rheumatic drugs (DMARDs) possess the potential to treat inflammation sufficiently. Thus, a treatment situation characterized by high (inflammatory) disease activity should be treated in terms of a change of the patients' ongoing anti-inflammatory DMARD regiment. Consequently, the project's focus is on pain, which cannot be attributed to inflammatory activity, i.e. the dimension of neuropathic pain.
"Eligibility criteria includes a Pain VAS of >50, but up to 100. Therefore, the Primary Outcome of a reduction of 20 translates to a % pain reduction between 20% to 40% depending, on the baseline VAS score. Would it not be more uniform to define a reduction of either 30% or 50% in VAS score?" c. When the protocol was made this was discussed a lot and your suggestion might have been useful and feasible as well, but we considered it practically more complicated:
We decided to consider an absolute 20-point reduction as significant and clinically relevant regardless of whether you start at VAS 50 or more. If we used the relative definition (e.g. -30 %), we would not accept the drop from 100 to 80 as clinically relevant
We chose the absolute change also based on what is easily done in practice: the clinician may be challenged by calculating percentage and this might be a cause for errors "The CBD portion of the trial is double blind and is a good design. The open label "add-on THC" arm will be subject to bias and has no comparator, so I do not see the benefit of studying it this way. Also, the merit of combination CBD:THC in responders would be useful to know." d. It is correct, that the double blind CBD/placebo part is the essential and scientifically most stringent part of the study. Nevertheless, the study design will give additional information about the combination of CBD and THC in patients, at least about the safety. We agree, that the ideal solution would have been a randomised study comparing both CBD, THC and placebo, for instance in a cross over design. Such a design would demand us to take care of the implicit risk of THC (ability to drive a car etc.) for all patients during the entire study period. It would also require a significantly larger study. We feel our design will provide important information on THC, despite the design, and it has the advantage that we know when THC is applied, and thereby can take the necessary precautions..
"The dose ratio of CBD to THC is potentially very variable. The Sativex product is a 1:1 ratio of the two drugs, whereas in this study CBD:TCH could potentially be 1.3:1 to 12:1, and will make interpretation of the THC component of the study even less reliable."
e. After end initiation during the first four weeks, the CBD application will be either daily 20 or 30 mg for an 8-week period. The corresponding target dose for THC application is 5 mg or 7.5 mg. Thus, the target ratio will vary between CBD: THC 2.6:1 and 6:1. We intend to get some safety data first on the THC application and see if the combination might lead to VAS reduction in those cases where the blinded CBD application did not.
"No study date is mentioned in the protocol, so I am not sure whether it is still not too late to make changes in the study design based on my comments."
f. We already have included the first patients.We expect the last patient last visit to take place in spring 2021
B. Reviewer 2. Jack E. Fincham, Ph.D. "This paper addresses a significantly important topic, the research methods and study design needs some clarification in the paper. I have made numerous suggested changes and/or additions throughout the manuscript."
Actions taken due to the changes and/ or additions as suggested by reviewer 2 are addressed briefly and sequential according to their appearance in the manuscript a. References specifying the prevalence of inflammatory rheumatic diseases are added b. Reference 18 has been replaced by the position paper presented by MA Fitzcharles in January this year. The position paper addresses the actual clinical problem in a more precise manner c. The article of RD Crean represents a study focusing on effects of cannabis on cognition; it is added to the reference list. d. Key references explaining the value and use of Patient related outcome measurements (PROMs) and the use of Visual Analogue Scores (VAS) in rheumatology are added e. The study has been approved by the Danish Medicines agency (DK-2018-010018) as addressed in chapter "Ethics and dissemination". The approval implies a detailed assessment of the test compounds manufacturing procedures. The study is also registered in the EudraCT system (EudraCT 2017-004226-15). The European standard demands the unambiguous chemical classification of the administrated compounds. The Danish reimbursement pilot program allows the use of complex herbal products (i.e. tea, inhalation). We chose the concept of the classical and chemically well defined approach, as defined by EudraCT. Thus, the study is not part of the Danish reimbursement program. f. The issue "justification why patients with AS & RA of low disease activity versus other levels of activity are selected" is addressed as answer b. to the questions of reviewer 1 g. Patients with rheumatoid arthritis and spondyloarthritis will commonly receive a disease modifying antirheumatic treatment based on conventional DMARDs (i.e Methotrexate) and/ or biologics (i.e. anti TNF). The treatment follows a well defined algorithm. Our choice and demand to focus on patients with a disease duration of at least 2 years is supposed to ensure the focus on presence of chronical pain in patients in which the inflammation appears to be under control h. The study demands that the analgesics that are recommended (i.e. paracetamol and/ or NSAIDS) are applied or have been applied without acceptable response i. The Danish national treatment register contains actualized data on ongoing treatment regiments. Thus, ongoing treatment regiments can easily be monitored j. The focus of the study is on RA and AS. By excluding concomitant other rheumatic diseases we try to avoid bias k. As the patients are well known and the study demands that their course of treatment has taken place for at least 2 years (i.e. at least 10, typically more than 15 or more clinical contacts), we assume that alcohol or drug abuse, as well as information about ongoing opioid and/ or cannabis treatment are well known information for the involved investigators l. Tablet CBD/placebo is applied either twice or thrice daily. We consider this approach a reasonable compromise between our attempt to gain information about drug security and effectiveness of CBD given in these -rather low -doses m. Please find the answer to the aspect "meaning for generalization of the study findings due to the concept of switching the patients between study protocols" beneath answer d to the questions of reviewer 1 n. Sativex® is a registered drug in DK. The patients will receive the information that efficacy of the applied test compound, as well as potential side effect may be comparable to Sativex®. The patient's rheumatologist will provide relevant project information in an outpatient setting. Chronicity of the chosen diseases and the inclusion criteria implies the typical project patient to be well known with a serious burden of disease. Tina Horsted, Danish specialist in pain management and anesthesiologist has been the primary source of relevant patient information and information about the tested compounds. Investigators and study nurses are specialists in the rheumatic field. o. The study has been approved by the Danish Medicines agency (DK-2018-010018) as addressed in chapter "Ethics and dissemination". The approval implies a detailed assessment of the manufacturing process inclusive the manufacturer (Glostrup pharmacy) p. Besides the assessments at week 12, 24 and 36, pain will also be assessed after 4 and 16 weeks by the study nurse, please find the corresponding information in figure 3 q. A key reference for the validity of the Pain Detect questionnaire is added r. The SF-36 is a commonly used tool in rheumatology and a well-integrated and validated part of DANBIO s. A key reference for the validity of measures in Ankylosing Spondylitis is added t. References for the psychological scales, i.e. the Trail Making Test (TMT), the Digit Symbol Substitution Test (DSST) and the Pittsburgh Sleep Quality Index and the Credibility/ expectancy Questionnaire (CEQ) are already provided u. Clinical data and outcomes are registered in an electronic Case Report Form, "eCRF" is the corresponding abbreviation v. A key reference for the validity and use of the DAS28-CRP is added Editorial requests:
1. Along with your revised manuscript, please include a copy of the SPIRIT checklist indicating the page/line numbers of your manuscript where the relevant information can be found (http://www.spiritstatement.org/)
Please find the Spirit checklist attached as Appendix 1, entitled "Manuscript 2018-028197 SPIRIT checklist"
2. Along with your revised manuscript, please provide an English language examples of the patient consent form as a supplementary file as per item #32 of the SPIRIT checklist.
Please find the English translation of the applied Danish consent form attached as Appendix 2, entitled "Can-Art consent statement, English version" 3. Please revise the title of your manuscript to include the research question, study design and setting. This is the preferred format of the journal.
4. Please also indicate that this is a study protocol in the title.
The title is revised according to the given instructions as mentioned under 3. and 4. 
GENERAL COMMENTS
The authors have addressed the questions I submitted, and have clarified the protocol rationale, and added further information to my satisfaction.
VERSION 2 -AUTHOR RESPONSE
Thank you for the positive review of our article and your editorial advice.
We have revised the manuscript thoroughly; in the revised manuscript, sections with alterations have been marked with yellow.
We hope you will find the revised manuscript suitable for publication.
Should there be any further comments, we would be pleased to address them.
Please find below our comments on your editorial recommendation:
1. Please add a colon after Ankylosing spondylitis in the title.
The title has been corrected 2. Please ensure that you have added some discussion of your response to ref 1, comment b (rationale for including patients with AS and RA of low disease activity), to the manuscript itself
The rationale for including patients with RA and AS of low disease activity has been added to the discussion section. Additionally, the explanation for the demand of a disease duration of 2 years has been added in the same section, as these issues are connected. (page 16, lines 12 -20) 3. Please do the same for the point from reviewer 2 about the rationale for including patients with a disease duration of 2 years or more Addressed under 2.
4. Please also include response i to reviewer 2 to the manuscript at an appropriate location (i. The Danish nationwide registry contains actualized data on ongoing treatment regiments. Thus, ongoing treatment regiments can easily be monitored).
The description of the DANBIO data and its advantages in the given context have been added to the MATERIALS AND METHODS section "Setting and study design", (page 7, lines 14 -16).
5. Please do the same for response k (k. As the patients are well known and the study demands that their course of treatment has taken place for at least 2 years (i.e. at least 10, typically more than 15 or more clinical contacts), we assume that alcohol or drug abuse, as well as information about ongoing opioid and/ or cannabis treatment are well known information for the involved investigators).
